[Analysis of Related Factors of Autologous Peripheral Hematopoietic Stem Cell Mobilization in Patients with Lymphoma and Myeloma].

Autor:	Yu XQ; Department of Hematology， The Affiliated Hospital of Jiangsu University, Zhengjiang 212001, Jiangsu Province, China., Wang LX; Department of Hematology， The Affiliated Hospital of Jiangsu University, Zhengjiang 212001, Jiangsu Province, China., Lei F; Department of Hematology， The Affiliated Hospital of Jiangsu University, Zhengjiang 212001, Jiangsu Province, China., Lu WP; Department of Hematology， The Affiliated Hospital of Jiangsu University, Zhengjiang 212001, Jiangsu Province, China., Fei XM; Department of Hematology， The Affiliated Hospital of Jiangsu University, Zhengjiang 212001, Jiangsu Province, China,E-mail:feixiaomingujs@126.com.
Jazyk:	čínština
Zdroj:	Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2022 Dec; Vol. 30 (6), pp. 1861-1867.
DOI:	10.19746/j.cnki.issn.1009-2137.2022.06.037
Abstrakt:	Objective: To explore the related factors affecting of autologous peripheral hematopoietic stem cell mobilization in patients with single center lymphoma and multiple myeloma. Methods: The clinical total of 30 patients with lymphoma or multiple myeloma who underwent autologous peripheral hematopoietic stem cell mobilization and transplantation in the Affiliated Hospital of Jiangsu University from March 2012 to December 2021 were retrospectively analyzed, including the patients' age, gender, disease type, chemotherapy course, mobilization scheme, collection times, CD34 + cell count, adverse events, days of neutrophil and platelet implantation after transplantation. The related factors affecting to the mobilization efficiency of peripheral blood stem cells was analyzed. Results: The mobilization scheme had a significant effect on the mobilization success rate of CD34 + cells. The mobilization success rate and optimal mobilization rate of intermediate-dose VP-16+G-CSF were higher than that of high-dose VP-16+G-CSF ( P <0.05); the mobilization success rate of patients with previous chemotherapy courses ≤4 was higher than that of patients with chemotherapy courses >4 (100% vs 72.22%, P <0.05); the mobilization success rate of lymphoma patients was lower than that of myeloma patients (66.67% vs 94.44%, P <0.05); the mobilization success rate of lymphoma patients who received intermediate-dose VP-16+G-CSF was higher than that received high-dose VP-16+G-CSF patients (100% vs 42.86%, P <0.05). Patients' gender, age, time from diagnosis to mobilization and disease status had no significant effect on the efficiency of stem cell mobilization. Fifteen patients (50%) had febrile neutropenia during stem cell mobilization. There was no statistical difference in the incidence of febrile neutropenia between the two mobilization schemes ( P >0.05); the incidence of severe thrombocytopenia in intermediate-dose VP-16+G-CSF group was higher than that in high-dose VP-16+G-CSF group ( P <0.05). There was no statistical difference in the time of granulocyte implantation and platelet implantation after stem cell transplantation in patients with different mobilization schemes ( P >0.05). Conclusion: Mobilization regime, the number of previous chemotherapy course and disease type affect the mobilization efficiency of stem cells. Intermediate dose VP-16+G-CSF can improve the mobilization efficiency of stem cell in lymphoma patients, but should pay attention to the risk of bleeding.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu